{
  "id": "30e463a5-1fc1-4709-bcea-52b19f8899ca",
  "compliance_id": "TEST-AI-1753816785",
  "product_name": "Keytruda Plus",
  "generic_name": "pembrolizumab-lenvatinib",
  "indication": "First-line treatment of advanced renal cell carcinoma",
  "therapeutic_area": "Oncology",
  "seo_reviewer_name": "SEO Reviewer",
  "seo_reviewer_email": "seo@3cubed.com",
  "nct_number": null,
  "sponsor": null,
  "development_stage": null,
  "line_of_therapy": null,
  "patient_population": null,
  "route_of_administration": null,
  "combination_partners": null,
  "primary_endpoints": null,
  "geographic_markets": null,
  "key_biomarkers": null,
  "target_age_groups": null,
  "client_reviewer_name": null,
  "client_reviewer_email": null,
  "mlr_reviewer_name": null,
  "mlr_reviewer_email": null,
  "submitter_email": "test.ai@pharma.com",
  "submitter_name": "Dr. AI Test",
  "ai_processing_status": "pending",
  "workflow_stage": "draft",
  "priority_level": "medium",
  "created_at": "2025-07-29T19:19:45.506426+00:00",
  "updated_at": "2025-07-29T19:19:45.506439+00:00",
  "ai_generated_content": null,
  "seo_keywords": null,
  "meta_title": null,
  "meta_description": null,
  "last_updated": null,
  "qa_status": null,
  "qa_score": null,
  "qa_feedback": null,
  "error_message": null,
  "mechanism_of_action": null,
  "dosage_form": null,
  "administration_route": null,
  "treatment_setting": null,
  "key_differentiators": null,
  "clinical_benefits": null,
  "client_reviewer": null,
  "geography": null,
  "raw_input_content": "\n        Product: Keytruda Plus (pembrolizumab + lenvatinib)\n        Indication: First-line advanced RCC\n        Key Data:\n        - CLEAR trial: mPFS 23.9 vs 9.2 months (HR 0.39)\n        - ORR: 71% vs 36%\n        - CR rate: 16.1% vs 4.2%\n        Target: Oncologists, urologists\n        "
}